Clinical DevelopmentLast reviewed April 2026

Patient-Reported Outcome(PRO)

An outcome measure that comes directly from the patient about their health condition without interpretation by a clinician or anyone else.

Usage Examples

The primary endpoint was change from baseline on the validated PRO measuring symptom severity.
PRO development included qualitative concept elicitation, cognitive interviews, and psychometric validation studies.

What is PRO?

Patient-Reported Outcomes (PROs) are health measures reported directly by the patient about their symptoms, functional status, or quality of life. FDA's 2009 PRO guidance (and 2023 patient-focused drug development guidance series) established that PRO measures supporting label claims must be validated instruments appropriate for the target population, with demonstrated content validity, construct validity, reliability, and ability to detect change.

PROs are increasingly used as primary or key secondary endpoints, especially in indications where patient-reported symptoms are the clinical truth (chronic pain, depression, irritable bowel syndrome, migraine). Label claims based on PROs require strong instrument validation and pre-specified statistical analysis. PRO development typically involves qualitative concept elicitation, instrument development, psychometric validation, and responsiveness testing — a multi-year process. Some disease areas have established PRO instruments; novel indications may require de novo PRO development.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside FDA PRO GUIDANCE 2009, FDA PFDD GUIDANCE SERIES.

FDAEMAPMDA

When This Matters

The primary endpoint was change from baseline on the validated PRO measuring symptom severity.
PRO development included qualitative concept elicitation, cognitive interviews, and psychometric validation studies.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

FDA PRO GUIDANCE 2009FDA PFDD GUIDANCE SERIES

Frequently Asked Questions

Demonstrated content validity (measures what it purports to measure in the target population), construct validity, reliability (consistency), and responsiveness (ability to detect change). Instrument validation typically requires qualitative research, psychometric testing, and responsiveness analysis across multiple studies.

Yes. FDA approves label claims based on PROs when the instrument is validated for the specific claim and population, analysis is pre-specified, and the effect is clinically meaningful. Symptom and function improvements are common PRO-based label claims.

PRO comes directly from the patient without interpretation. Clinician-reported outcomes (ClinROs) involve clinical judgment based on patient observation or interview. Both are valid outcomes; PROs are preferred when the construct of interest is the patient's subjective experience.